[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse KRT8

Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus, nucleoplasm Nucleus matrix
Domain PF00038 Intermediate filament protein
PF16208 Keratin type II head
Function

Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001701 in utero embryonic development
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0009415 response to water
GO:0010035 response to inorganic substance
GO:0010927 cellular component assembly involved in morphogenesis
GO:0030239 myofibril assembly
GO:0031032 actomyosin structure organization
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0042692 muscle cell differentiation
GO:0045214 sarcomere organization
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0051146 striated muscle cell differentiation
GO:0051599 response to hydrostatic pressure
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0060706 cell differentiation involved in embryonic placenta development
GO:0061458 reproductive system development
GO:0071356 cellular response to tumor necrosis factor
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097284 hepatocyte apoptotic process
GO:1904019 epithelial cell apoptotic process
Molecular Function GO:0097110 scaffold protein binding
Cellular Component GO:0005882 intermediate filament
GO:0016010 dystrophin-associated glycoprotein complex
GO:0016363 nuclear matrix
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030018 Z disc
GO:0031674 I band
GO:0034399 nuclear periphery
GO:0042383 sarcolemma
GO:0043034 costamere
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
GO:0045095 keratin filament
GO:0045111 intermediate filament cytoskeleton
GO:0090665 glycoprotein complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-6805567: Keratinization
Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KRT8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KRT8 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KRT8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3210.589
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3670.756
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8240.388
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.350.505
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5660.845
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0760.984
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5260.512
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.6350.208
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6220.646
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0950.971
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1640.967
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5830.00258
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KRT8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KRT8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KRT8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KRT8.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KRT8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KRT8 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KRT8 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKRT8
Namekeratin 8, type II
Aliases CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KRT8 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting KRT8.
ID Name Drug Type Targets #Targets
DB00031TenecteplaseBiotechANXA2, CALR, CANX, CLEC3B, FGA, KRT8, LRP1, PLAUR, PLG, SERPINB2, ......11
DB06245LanoteplaseBiotechANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......17
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141